Fortis Healthcare Limited

NSE: FORTIS · Healthcare · Lot size: 775

OverviewOption ChainOI AnalysisFII / DIIMax Pain

Fortis Healthcare Limited Share Price & Analysis

₹952Updated 22 Jul 2026, 03:30 pm IST
LTP
₹952
—
Open
₹969
High
₹969.7
Low
₹945.5
Close
₹969
52W High
₹1,105
52W Low
₹767
Volume
637K
Lot Size
775
Sector
Healthcare
Market Cap
₹72K Cr
Face Value
₹10
Large CapNIFTY 200NIFTY 500MIDCAP 100

Price Chart

Fundamentals

P/E
67.9
Sector P/E
54.4
P/B
7.27
EPS
₹12.72
ROE
11.3%
ROCE
13.5%
D/E Ratio
0.35
Div Yield
0.1%
Book Value
₹131
+

Strengths

  • ✓Low debt relative to equity (D/E 0.4x)

Peer Comparison

CompanyCMPMkt CapP/EP/BROE %ROCE %D/E
SUNPHARMA
Sun Pharmaceutical Industries Limited
₹1,944
₹4.6L Cr37.35.591620.50.07
DIVISLAB
Divi's Laboratories Limited
₹7,388
₹1.9L Cr73.411.7116.5220.01
TORNTPHARM
Torrent Pharmaceuticals Limited
₹5,040
₹1.6L Cr73.620.3227.415.20.33
APOLLOHOSP
Apollo Hospitals Enterprise Limited
₹8,939
₹1.3L Cr64.913.5622.117.90.88
CIPLA
Cipla Limited
₹1,416
₹1.1L Cr30.13.3211.615.50.01
ZYDUSLIFE
Zydus Lifesciences Limited
₹1,123
₹1.1L Cr214.1721.221.10.38
LUPIN
Lupin Limited
₹2,405
₹1.1L Cr19.64.928.729.90.32

Showing 7 peers in the same sector · Sorted by market cap

Shareholding Pattern

FORTIS · as of Mar 2026

Promoters31.17%
FII27.40%▲0.63
DII29.46%▼0.59
Public11.98%▼0.04
CategoryDec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters31.17%31.17%31.17%31.17%31.17%31.17%
FII23.72%23.24%23.31%25.26%26.77%27.40%
DII29.42%31.14%32.31%30.73%30.05%29.46%
Public15.71%14.44%13.22%12.83%12.02%11.98%

Corporate Events

Dividend - Re 1 Per Share

Dividend23 Jul 2026

To consider and approve the financial results for the period ended March 31, 2026 and recommendation of Final Dividend for the year ended March 31, 2026.

Dividend21 May 2026

Dividend - Re 1 Per Share

Dividend24 Jul 2025

Dividend - Re 1 Per Share

Dividend23 Jul 2024

Dividend - Re 1 Per Share

Dividend19 Jul 2023

Latest News

All news →

Fortis reappoints Dr. Ashutosh Raghuvanshi as MD & CEO

*Fortis reappoints Dr. Ashutosh Raghuvanshi as MD & CEO* — Fortis Healthcare has reappointed Dr. Ashutosh Raghuvanshi as Managing Director and CEO. The reappointment underscores leadership continuity and strategic stability. Investors may view this positively amid competitive healthcare sector dynamics. 📊 *STOCKS:* FORTIS | 🏢 *SECTOR:* Healthcare | #MEDIUMIMPACT #Leadership

NSE Filing8 Jul
High Impact

Fortis Healthcare publishes newspaper notice as per regulatory requirement

*Fortis Healthcare publishes newspaper notice as per regulatory requirement.* This is a routine corporate filing submitted to the NSE, typically related to shareholder communications or disclosures. No financial or operational update was provided. Such filings are standard compliance actions. 📊 *STOCKS:* FORTIS | 🏢 *SECTOR:* Healthcare | #LOWIMPACT #Regulatory

NSE Filing9 Jul
Low Impact

Fortis Healthcare subsidiary receives income tax order

*Fortis Healthcare subsidiary receives income tax order* Fortis Healthcare announced an income tax order concerning its wholly owned subsidiary under Regulation 30 of SEBI Listing Regulations. The details of the order, including financial implications, were not disclosed in the filing. This regulatory update pertains to compliance and tax assessment for the subsidiary entity. 📊 *STOCKS:* FORTIS | 🏢 *SECTOR:* Corporate | #LOWIMPACT #Regulation

NSE Filing17 Jun
Low Impact

MSCI rejig: Fortis, Paytm promoted; Tata Elxsi, CONCOR demoted

*MSCI India index rejig reshuffles key stock allocations.* **Fortis** and **Paytm** promoted to Standard index, while **Tata Elxsi** and **CONCOR** demoted. Changes effective after market close, affecting passive fund flows and portfolio rebalancing. Index composition shifts may trigger institutional buying/selling activity in affected stocks. 📊 *STOCKS:* $FORTIS | $PAYTM | $TATAELXSI | $CONCOR | 🏢 *SECTOR:* CapitalMarkets | #MEDIUMIMPACT #IndexRejig

Moneycontrol.com24 Apr
Medium Impact

Financials

Quarterly Results

MetricDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
Revenue
₹2.3K Cr
▼2.8%
₹2.3K Cr
▲7.6%
₹2.2K Cr
▲8.0%
₹2.0K Cr
▲4.1%
₹1.9K Cr
▼3.0%
₹2.0K Cr
▲6.9%
₹1.9K Cr
▲4.1%
₹1.8K Cr
Op. Profit
₹506 Cr
▼9.0%
₹556 Cr
▲13.2%
₹491 Cr
▲12.9%
₹435 Cr
▲16.0%
₹375 Cr
▼13.8%
₹435 Cr
▲26.8%
₹343 Cr
▼10.0%
₹381 Cr
OPM
22.0%
▼8.3%
24.0%
▲4.3%
23.0%
▲4.5%
22.0%
▲15.8%
19.0%
▼13.6%
22.0%
▲22.2%
18.0%
▼14.3%
21.0%
Net Profit
₹197 Cr
▼40.1%
₹329 Cr
▲23.2%
₹267 Cr
▲42.0%
₹188 Cr
▼26.0%
₹254 Cr
▲31.6%
₹193 Cr
▲10.9%
₹174 Cr
▼14.3%
₹203 Cr
EPS (₹)
2.57
▼39.7%
4.26
▲23.5%
3.45
▲41.4%
2.44
▼25.6%
3.28
▲40.2%
2.34
▲6.4%
2.2
▼7.2%
2.37

Values in ₹ Cr · Source: Screener.in

Annual Profit & Loss

MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Revenue
₹9.1K Cr
▲17.3%
₹7.8K Cr
▲12.9%
₹6.9K Cr
▲9.4%
₹6.3K Cr
▲10.1%
₹5.7K Cr
▲41.9%
₹4.0K Cr
▼13.0%
₹4.6K Cr
▲3.6%
₹4.5K Cr
▼2.0%
₹4.6K Cr
▼0.3%
₹4.6K Cr
Expenses
₹7.0K Cr
▲13.7%
₹6.2K Cr
▲10.1%
₹5.6K Cr
▲8.3%
₹5.2K Cr
▲11.8%
₹4.6K Cr
▲28.2%
₹3.6K Cr
▼9.8%
₹4.0K Cr
▼5.1%
₹4.2K Cr
▼1.1%
₹4.3K Cr
▲1.6%
₹4.2K Cr
Op. Profit
₹2.1K Cr
▲31.3%
₹1.6K Cr
▲25.2%
₹1.3K Cr
▲15.2%
₹1.1K Cr
▲3.0%
₹1.1K Cr
▲164.6%
₹404 Cr
▼33.8%
₹610 Cr
▲164.1%
₹231 Cr
▼15.7%
₹274 Cr
▼22.6%
₹354 Cr
OPM
23.0%
▲15.0%
20.0%
▲11.1%
18.0%
▲5.9%
17.0%
▼10.5%
19.0%
▲90.0%
10.0%
▼23.1%
13.0%
▲160.0%
5.0%
▼16.7%
6.0%
▼25.0%
8.0%
Other Income
₹45 Cr
▲509.1%
₹-11 Cr
▼117.2%
₹64 Cr
▼59.2%
₹157 Cr
▼57.2%
₹367 Cr
▲286.3%
₹95 Cr
▼24.6%
₹126 Cr
▼44.7%
₹228 Cr
▲133.1%
₹-689 Cr
▼206.2%
₹649 Cr
Interest
₹314 Cr
▲70.7%
₹184 Cr
▲40.5%
₹131 Cr
▲1.6%
₹129 Cr
▼12.2%
₹147 Cr
▼11.4%
₹166 Cr
▼19.0%
₹205 Cr
▼39.2%
₹337 Cr
▲30.6%
₹258 Cr
▲12.7%
₹229 Cr
Depreciation
₹449 Cr
▲16.3%
₹386 Cr
▲12.9%
₹342 Cr
▲8.2%
₹316 Cr
▲5.0%
₹301 Cr
▲3.4%
₹291 Cr
▼0.3%
₹292 Cr
▲25.3%
₹233 Cr
▼2.5%
₹239 Cr
▲7.7%
₹222 Cr
PBT
₹1.4K Cr
▲35.7%
₹1.0K Cr
▲17.4%
₹858 Cr
▲5.4%
₹814 Cr
▼17.6%
₹988 Cr
▲2197.7%
₹43 Cr
▼82.0%
₹239 Cr
▲317.3%
₹-110 Cr
▲87.9%
₹-912 Cr
▼265.2%
₹552 Cr
Tax %
22.0%
▲10.0%
20.0%
▼20.0%
25.0%
▲13.6%
22.0%
▲10.0%
20.0%
▼91.3%
230.0%
▲271.0%
62.0%
▼39.8%
103.0%
▲5050.0%
2.0%
▼84.6%
13.0%
Net Profit
₹1.1K Cr
▲31.5%
₹809 Cr
▲25.4%
₹645 Cr
▲1.9%
₹633 Cr
▼19.9%
₹790 Cr
▲1510.7%
₹-56 Cr
▼161.5%
₹91 Cr
▲140.6%
₹-224 Cr
▲76.0%
₹-934 Cr
▼295.0%
₹479 Cr
EPS (₹)
13.8
▲34.5%
10.26
▲29.4%
7.93
▲1.7%
7.8
▲6.1%
7.35
▲606.9%
-1.45
▼288.3%
0.77
▲119.4%
-3.96
▲79.7%
-19.46
▼339.1%
8.14
Div Payout
7.0%
▼30.0%
10.0%
▼23.1%
13.0%
▲0.0%
13.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%

Values in ₹ Cr · Source: Screener.in

Balance Sheet

ItemSep 2025Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017
Liabilities
Equity Capital
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲0.0%
₹755 Cr
▲45.5%
₹519 Cr
▲0.2%
₹518 Cr
Reserves
₹8.7K Cr
▲6.3%
₹8.2K Cr
▲18.2%
₹6.9K Cr
▲6.5%
₹6.5K Cr
▲19.6%
₹5.4K Cr
▲1.1%
₹5.4K Cr
▼9.2%
₹5.9K Cr
▲1.0%
₹5.8K Cr
▲65.0%
₹3.5K Cr
▼23.4%
₹4.6K Cr
Borrowings
₹3.2K Cr
▲29.1%
₹2.5K Cr
▲114.3%
₹1.2K Cr
▲24.7%
₹926 Cr
▼26.2%
₹1.3K Cr
▼18.0%
₹1.5K Cr
▼4.0%
₹1.6K Cr
▼20.7%
₹2.0K Cr
▲2.4%
₹2.0K Cr
▼11.5%
₹2.2K Cr
Other Liabilities
₹2.4K Cr
▲20.4%
₹2.0K Cr
▼52.2%
₹4.2K Cr
▲5.9%
₹3.9K Cr
▼3.9%
₹4.1K Cr
▲26.9%
₹3.2K Cr
▲15.6%
₹2.8K Cr
▼3.3%
₹2.9K Cr
▲17.1%
₹2.5K Cr
▲10.2%
₹2.2K Cr
Total Liabilities
₹15.0K Cr
▲12.2%
₹13.4K Cr
▲3.1%
₹13.0K Cr
▲7.3%
₹12.1K Cr
▲5.0%
₹11.5K Cr
▲6.0%
₹10.9K Cr
▼1.5%
₹11.0K Cr
▼3.9%
₹11.5K Cr
▲35.5%
₹8.5K Cr
▼11.6%
₹9.6K Cr
Assets
Fixed Assets
₹11.7K Cr
▲12.3%
₹10.4K Cr
▲5.6%
₹9.9K Cr
▲4.8%
₹9.4K Cr
▲0.1%
₹9.4K Cr
▲7.0%
₹8.8K Cr
▼0.0%
₹8.8K Cr
▲3.8%
₹8.5K Cr
▲69.8%
₹5.0K Cr
▼7.9%
₹5.4K Cr
CWIP
₹306 Cr
▼24.8%
₹407 Cr
▼24.9%
₹542 Cr
▲137.7%
₹228 Cr
▲18.1%
₹193 Cr
▲17.0%
₹165 Cr
▼19.1%
₹204 Cr
▼54.7%
₹450 Cr
▲99.1%
₹226 Cr
▼15.7%
₹268 Cr
Investments
₹220 Cr
▲30.2%
₹169 Cr
▼26.5%
₹230 Cr
▲9.5%
₹210 Cr
▲101.9%
₹104 Cr
▼44.1%
₹186 Cr
▲6.3%
₹175 Cr
▼35.2%
₹270 Cr
▼84.4%
₹1.7K Cr
▼7.8%
₹1.9K Cr
Other Assets
₹2.8K Cr
▲17.1%
₹2.4K Cr
▲2.2%
₹2.3K Cr
▲4.5%
₹2.2K Cr
▲23.4%
₹1.8K Cr
▲5.1%
₹1.7K Cr
▼7.5%
₹1.9K Cr
▼19.0%
₹2.3K Cr
▲49.8%
₹1.5K Cr
▼24.4%
₹2.0K Cr
Total Assets
₹15.0K Cr
▲12.2%
₹13.4K Cr
▲3.1%
₹13.0K Cr
▲7.3%
₹12.1K Cr
▲5.0%
₹11.5K Cr
▲6.0%
₹10.9K Cr
▼1.5%
₹11.0K Cr
▼3.9%
₹11.5K Cr
▲35.5%
₹8.5K Cr
▼11.6%
₹9.6K Cr

Values in ₹ Cr · Source: Screener.in

Cash Flow Statement

ItemMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Operating CF
₹1.4K Cr
▲29.5%
₹1.1K Cr
▲33.8%
₹822 Cr
▼5.0%
₹865 Cr
▲78.4%
₹485 Cr
▲182.0%
₹172 Cr
▲196.1%
₹-179 Cr
▼136.3%
₹493 Cr
▼49.0%
₹966 Cr
▲395.4%
₹195 Cr
Investing CF
₹-780 Cr
▲12.3%
₹-889 Cr
▼139.0%
₹-372 Cr
▲25.7%
₹-501 Cr
▼282.4%
₹-131 Cr
▼307.9%
₹63 Cr
▲101.9%
₹-3.3K Cr
▼884.7%
₹-333 Cr
▲66.7%
₹-1.0K Cr
▼920.5%
₹122 Cr
Financing CF
₹-714 Cr
▼730.2%
₹-86 Cr
▲81.7%
₹-471 Cr
▲8.9%
₹-517 Cr
▼261.5%
₹-143 Cr
▲83.4%
₹-862 Cr
▼120.2%
₹4.3K Cr
▲733.5%
₹-672 Cr
▼359.5%
₹259 Cr
▲173.2%
₹-354 Cr
Net Cash Flow
₹-70 Cr
▼156.0%
₹125 Cr
▲695.2%
₹-21 Cr
▲86.3%
₹-153 Cr
▼172.2%
₹212 Cr
▲133.8%
₹-627 Cr
▼178.5%
₹799 Cr
▲255.8%
₹-513 Cr
▼328.0%
₹225 Cr
▲708.1%
₹-37 Cr
Free Cash Flow
₹591 Cr
▲243.6%
₹172 Cr
▼53.1%
₹367 Cr
▼51.1%
₹750 Cr
▲173.7%
₹274 Cr
▲682.9%
₹35 Cr
▲113.4%
₹-261 Cr
▼159.7%
₹437 Cr
▼36.6%
₹689 Cr
▲525.3%
₹-162 Cr

Values in ₹ Cr · Source: Screener.in

Key Ratios History

MetricMar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Debtor Days
37d
▲12.1%
33d
▼2.9%
34d
▲3.0%
33d
▼19.5%
41d
▲13.9%
36d
▼18.2%
44d
▲15.8%
38d
▲0.0%
38d
▼2.6%
39d
Inventory Days
23d
▼4.2%
24d
▼22.6%
31d
▼6.1%
33d
▲13.8%
29d
▼3.3%
30d
▲36.4%
22d
▼8.3%
24d
▲4.3%
23d
▲0.0%
23d
Days Payable
161d
▼1.8%
164d
▼8.4%
179d
▲0.6%
178d
▼13.2%
205d
▼9.3%
226d
▼23.6%
296d
▲6.1%
279d
▲29.8%
215d
▼1.4%
218d
Cash Conv. Cycle
-101d
▲5.6%
-107d
▲7.0%
-115d
▼2.7%
-112d
▲17.0%
-135d
▲16.1%
-161d
▲30.0%
-230d
▼6.0%
-217d
▼40.0%
-155d
▲0.6%
-156d
Working Capital Days
-30d
▲75.8%
-124d
▼463.6%
-22d
▲37.1%
-35d
▲37.5%
-56d
▲62.7%
-150d
▲35.9%
-234d
▼107.1%
-113d
▼29.9%
-87d
▼26.1%
-69d
ROCE
12.0%
▲20.0%
10.0%
▲0.0%
10.0%
▲0.0%
10.0%
▲400.0%
2.0%
▼50.0%
4.0%
▼33.3%
6.0%
▲100.0%
3.0%
▼72.7%
11.0%
▲266.7%
3.0%

Source: Screener.in · Lower days = better efficiency

Deep Dive Analysis

Option Chain
Strike-wise OI & IV
OI Analysis
PCR, buildup type
FII / DII
Institutional flows
Max Pain
Writer pain levels

About Fortis Healthcare Limited

FHL was incorporated in February 1996. The company’s first healthcare facility became operational in Mohali, Punjab in 2001. It is a leading integrated healthcare service provider in India. The healthcare verticals of the company primarily comprise hospitals, diagnostics and day care specialty facilities. Currently, the company operates its healthcare delivery services in India, Nepal, Dubai and Sri Lanka with 36 healthcare facilities with approximately 4,000 operational beds. [1]

Healthcare · Healthcare Services

Related Analysis

Same Sector

ALKEM
Alkem Laboratories Limited
Neutral
APOLLOHOSP
Apollo Hospitals Enterprise Limited
Neutral
AUROPHARMA
Aurobindo Pharma Limited
Neutral
BIOCON
Biocon Limited
Neutral
CIPLA
Cipla Limited
Neutral

Frequently Asked Questions

What is Fortis Healthcare Limited share price today?▾
Fortis Healthcare Limited (FORTIS) is currently trading at ₹952 on NSE, as of the last market session. Prices update daily after market close on MarketNetra.
Is Fortis Healthcare Limited available in F&O (Futures & Options)?▾
Yes, Fortis Healthcare Limited (FORTIS) is part of the NSE F&O segment with a lot size of 775 shares. Options are available with monthly expiry contracts. You can track the full option chain and OI analysis on MarketNetra.
What is Fortis Healthcare Limited 52-week high and low?▾
Fortis Healthcare Limited's 52-week high is ₹1,105 and the 52-week low is ₹767. The current price of ₹952 is 13.8% below the 52W high.
What is Fortis Healthcare Limited P/E ratio?▾
Fortis Healthcare Limited's current P/E ratio is 67.9. This indicates the market is paying ₹67.9 for every ₹1 of earnings. Compare this to the sector average to assess relative valuation.
How to trade Fortis Healthcare Limited options?▾
Fortis Healthcare Limited options are traded on NSE with monthly expiry contracts (lot size: 775 shares). To trade FORTIS options: select your expiry on the option chain page, identify key OI strikes, check the PCR and buildup type on OI analysis, and review FII/DII flows for institutional sentiment before taking a position.